| 产品详情 |
| Edit |   |
|---|
| Product Name | PTC2 Mutant (PRKAR1A-RET), Active |
|---|
| Description | PRKAR1A (1-236)-RET (713-end). MW: ~105 kDa. Description: Recombinant human RET/PTC2, the fusion protein [PRKAR1A (1-236)-RET (713-end)], was expressed by baculovirus in Sf9 insect cells using an N-terminal GST tag.Scientific Background: RET/PTC2 is fused of the tyrosine-kinase domain of proto-RET with the regulatory subunit R/A of c-AMP-dependent protein kinase A, by transforming a chromosomal translocation at t (10;17) (q11.2;q23) (1). The RET/PTC oncoproteins display constitutive TK activ |
|---|
| Size | 0.005 mg, 0.01 mg |
|---|
| Concentration | n/a |
|---|
| Applications | Kinase Assay, Western Blot (WB) |
|---|
| Other Names | [Homo sapiens protein kinase cAMP-dependent type I regulatory subunit alpha (PRKAR1A), transcript variant 1, mRNA; cAMP-dependent protein kinase type I-alpha regulatory subunit; cAMP-dependent protein kinase type I-alpha regulatory subunit; protein kinase cAMP-dependent type I regulatory subunit alpha; Tissue-specific extinguisher 1; TSE1] |
|---|
| Gene, Accession, CAS # | PTC2, Gene ID: 5573, Accession: NM_002734.4 |
|---|
| Catalog # | MBS515644 |
|---|
| Price | |
|---|
| Order / More Info | PTC2 Mutant (PRKAR1A-RET), Active from MYBIOSOURCE INC. |
|---|
| Product Specific References | 1. Gabriella S. et al: A t (10; 17) translocation creates the RET/PTC2 chimeric transforming sequence in papillary thyroid carcinoma. Genes, Chromosomes and Cancer. 9:244-250 (1994). 2. M G Borrello, et al: The full oncogenic activity of Ret/ptc2 depends on tyrosine 539, a docking site for phospholipase Cgamma. Mol Cell Biol. May 1996; 16 (5): 2151 -2163. |
|---|
| 产品资料 |
|
|